Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
What happened
The Food and Drug Administration (FDA) announced the availability of a final guidance document titled "Psychedelic Drugs: Considerations for Clinical Investigations." This guidance, signed by Donald Trump, provides recommendations for companies designing clinical trials to evaluate psychedelic drugs for psychiatric and substance use disorders. This final guidance completes the draft guidance issued on June 26, 2023.
Why it matters
This guidance will shape how new psychedelic-based treatments are tested and potentially brought to market, influencing the future availability of these drugs for patients. It aims to address the unique challenges of studying psychedelic drugs in clinical trials.
Who it affects
- ›Companies developing psychedelic drugs
- ›Patients with psychiatric or substance use disorders
- ›Clinical investigators of psychedelic drugs
- ›Food and Drug Administration (FDA)
The receipts are official. The summary is ours.
Read on Federal Register ↗Summaries are generated from the official text and may simplify or omit nuance. The official document is the source of truth.